[1] |
CAO Kai, QIAN Peipei, GAO Xin, YANG Futian, ZHAO Liang, XU Bingxin, ZHANG Xianjun.
Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 799-804.
|
[2] |
CHEN Lingbin, HUANG Zhixiong, ZHENG Cailin, WU Jinneng, CHEN Zhou.
Adverse Event Signals for Osimertinib-Induced Muscle Toxicity Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 447-451.
|
[3] |
GUO Yuansheng, ZUO Tiantian, LIU Li'na, WEI Feng, DONG Zhe, LI Jing, JIN Hongyu, MA Shuangcheng.
Twenty-eight elements in Coicis Semen and risk assessment by stir-frying with bran by inductively coupled plasma-mass spectrometry
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1008-1013.
|
[4] |
ZHAO Peipei, WEN Baoshu.
Regulation of cellular and gene therapies at home and abroad
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024.
|
[5] |
LU De, XU Wenyan, LIU Jinxin, PEI Yusheng.
Discussion and analysis of bacterial endotoxin problems in FDA warning letters
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 857-862.
|
[6] |
ZHONG Hong, CHEN Hong, ZHANG Xuanyi, DENG Huiyuan, LUO Xianglin, WAN Jie, KONG Wenqiang.
Detection and analysis of signals of adverse events induced by deferasirox based on FAERS
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 931-935.
|
[7] |
ZHU Yan, LI Qingna, ZHU Lan, XIE Jiang’an, YAO Keyu, HUANG Guangrui, YANG Xiaolin, GUAN Jian.
Current situation and suggestions concerning the implementation of MedDRA in drug monitoring in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 746-751.
|
[8] |
YOU Xiaoyan, ZHENG Yingying, WANG Xianying.
Data-mining and analysis of adverse events signals for infliximab based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 335-340.
|
[9] |
WU Tingxi, ZHAO Zhigang, SHI Yanfeng, ZHANG Yang, ZHANG Yinan, ZHU Bin.
Risk assessment of colchicine-associated neurological adverse events based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 341-345.
|
[10] |
ZAN Ke, ZHAO Lei, JIANG Dacheng, WANG Ying, JIN Hongyu, MA Yu, MA Shuangcheng.
Determination of 135 pesticide residues in Farfarae Flos by UPLC-MS/MS and risk assessment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 885-890.
|
[11] |
WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin.
One case of pharmaceutical care of drug exposure during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
|
[12] |
WANG Ran, FENG Xin, DU Boran.
Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
|
[13] |
NIE Lixing, WANG Xinping, LI Jing, DAI Zhong, KANG Shuai, MA Shuangcheng.
Content analysis and risk assessment of aristolochic acids in Chinese medicinal materials (decoction pieces)
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 553-559.
|
[14] |
YAO Keyu, ZHANG Shuqi, JIN Rui, LIU Lihong, ZHU Yan.
Comparative study on data set of drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 568-573.
|
[15] |
NIE Lixing, CHEN Jia, ZHANG Ye, ZHAO Hui, DAI Zhong, MA Shuangcheng.
Comprehensive tests and risk assessment of exogenous harmful residues in Isatidis Radix
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 379-382.
|